Grant: Proof of Principle Program - Phase I
McGill University
$146,000.00
Development of novel OXE receptor antagonists for asthma
FY 2009-10
Summary
Asthma and other allergic diseases are widespread, affecting up to 30% of the general population. They are characterized by the infiltration of white blood cells into the lungs or other tissues, where they release various substances that cause inflammation. One type of white blood cell, the eosinophil, is the hallmark of allergic diseases and is found in large numbers in the airways of individuals with asthma and allergic rhinitis. These cells play an important role in defending the body from parasitic infections, but in asthma and other allergic diseases they cause deleterious changes including lung damage and tissue remodelling. Eosinophils are attracted to the lungs by locally produced factors, including lipids and peptides. The most prominent chemoattractant lipid is 5-oxo-ETE, a substance formed from tissue lipids by a series of enzyme-catalyzed oxidative reactions. The actions of 5-oxo-ETE on eosinophils are due to its strong binding to a molecule on the surface of the cell known as the OXE receptor. This interaction results in activation of the eosinophil and its movement towards the source of 5-oxo-ETE, where it is most highly concentrated. If the interaction between 5-oxo-ETE and the OXE receptor can be prevented this could drastically reduce the numbers of eosinophils in the airways in asthma and allergic rhinitis. To accomplish this we have synthesized and tested a series of chemical substances that bind to the OXE receptor without activating it and thereby prevent its activation by 5-oxo-ETE. Some of these substances are potent inhibitors of 5-oxo-ETE-induced eosinophil movement through artificial membranes. The objective of this proposal is to test the most active compounds in an animal used as a model of human asthma for their ability to block the accumulation of eosinophils in the lungs. If our experiments are successful, this could lead to the development of a new drug that could be used to treat asthma and allergic rhinitis.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
184832
Name
Powell William S
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development of novel OXE receptor antagonists for asthma
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$146,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
5-Oxo-Ete; Antagonists; Eicosanoids; Eosinophils; Inflammation; Neutrophils
Abstract
Asthma and other allergic diseases are widespread, affecting up to 30% of the general population. They are characterized by the infiltration of white blood cells into the lungs or other tissues, where they release various substances that cause inflammation. One type of white blood cell, the eosinophil, is the hallmark of allergic diseases and is found in large numbers in the airways of individuals with asthma and allergic rhinitis. These cells play an important role in defending the body from parasitic infections, but in asthma and other allergic diseases they cause deleterious changes including lung damage and tissue remodelling. Eosinophils are attracted to the lungs by locally produced factors, including lipids and peptides. The most prominent chemoattractant lipid is 5-oxo-ETE, a substance formed from tissue lipids by a series of enzyme-catalyzed oxidative reactions. The actions of 5-oxo-ETE on eosinophils are due to its strong binding to a molecule on the surface of the cell known as the OXE receptor. This interaction results in activation of the eosinophil and its movement towards the source of 5-oxo-ETE, where it is most highly concentrated. If the interaction between 5-oxo-ETE and the OXE receptor can be prevented this could drastically reduce the numbers of eosinophils in the airways in asthma and allergic rhinitis. To accomplish this we have synthesized and tested a series of chemical substances that bind to the OXE receptor without activating it and thereby prevent its activation by 5-oxo-ETE. Some of these substances are potent inhibitors of 5-oxo-ETE-induced eosinophil movement through artificial membranes. The objective of this proposal is to test the most active compounds in an animal used as a model of human asthma for their ability to block the accumulation of eosinophils in the lungs. If our experiments are successful, this could lead to the development of a new drug that could be used to treat asthma and allergic rhinitis.
Competitiondate
200904
Approvedterm2
1 yr 0 mth
Pinamesdelim
Powell, William S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $146,000~ $0~